Medical Communications

Showing 15 posts of 6408 posts found.

pounds_stacked

Regulators get aggressive on matters excessive

June 29, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CMA, Drug pricing, European Commission, Pfizer, aspen

Gustaf Duhs, Partner at Stevens & Bolton, discusses the recent cases of regulators becoming firmer with drug companies over their …

Regenacy names new President and CEO

June 28, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Regenacy, appointment

Simon S Jones has been revealed as the new President and Chief Executive Officer of Regenacy Pharmaceuticals, a biopharma company …
rosemarie_finley_photo

Myeloma UK’s new CEO begins her role

June 28, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Myeloma UK

Myeloma UK, the only organisation in the UK dealing exclusively with myeloma, will have a new CEO in place from …
hack

MSD struck in second global cyber attack

June 28, 2017 Medical Communications, Research and Development Cyber attack, MSD

Following the recent and heavily-publicised ransomware attack which hit the NHS in the UK and almost 100 other countries, the …
fdaoutsideweb

FDA weighs in to improve generic competition

June 27, 2017 Medical Communications, Sales and Marketing FDA, generic drugs, pricing debate

Since Scott Gottlieb was appointed Commissioner, the FDA has been on a marked push to tackle two areas: drug pricing …
kress

Biogen appoint new Head of Global Therapeutic Operations

June 27, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Jean-Paul Kress

Biogen announced that Jean-Paul Kress has been appointed to the position of Executive Vice President and President, International, and Head …
novartis_side_building

UK launch of two Novartis biosimilars could cut NHS costs

June 27, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Erelzi, Novartis, Rixathon, Sandoz, biosimilar, etanercept, rituximab

Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and …
filing_cabinet

Number of patients at risk from NHS mail mistake revealed

June 27, 2017 Manufacturing and Production, Medical Communications Department of Health, Jeremy Hunt, NHS, NHS England

According to the patient records that have been examined so far, at least 1,700 may have been put at risk …
shutterstock_57369385

Drug Combinations and Emerging Interactions

June 26, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drug combinations, drug resistance, feature

Pamela Yeh, Assistant Professor at the Department of Ecology and Evolutionary Biology, University of California, Los Angeles, discusses how drug …
nhs_parliament_2_4

Public dissatisfaction with NHS found to be growing, says BMA

June 26, 2017 Medical Communications, Sales and Marketing BMA, NHS

The British Medical Association has revealed that a poll, conducted by British doctors, shows that levels of public dissatisfaction with …

Astellas receives further year suspension from ABPI

June 26, 2017 Medical Communications, Sales and Marketing ABPI, Astellas

The Association of the British Pharmaceutical Industry (ABPI) has announced that it has taken the unusual step of extending the …

Pfizer’s biosimilar gets a second knock-back from FDA

June 23, 2017 Medical Communications, Sales and Marketing Amgen, Epogen, FDA, Pfizer

Pfizer has been dealt a stinging blow by the FDA, after it received a second complete response letter from the …
novartis_outside_1

Novartis lung cancer combo receives FDA approval

June 23, 2017 Medical Communications, Sales and Marketing NSCLC, Novartis

Novartis has revealed that its drug Tafinlar (dabrafenib) has received approval from the FDA for use in combination with Mekinist …
The Gateway to Local Adoption Series

Latest content